122.28
1.02%
+1.23
After Hours:
122.28
Illumina Inc stock is currently priced at $122.28, with a 24-hour trading volume of 813.70K.
It has seen a +1.02% increased in the last 24 hours and a -8.61% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $120.0 pivot point. If it approaches the $123.1 resistance level, significant changes may occur.
Previous Close:
$121.05
Open:
$119.65
24h Volume:
813.70K
Market Cap:
$19.47B
Revenue:
$4.50B
Net Income/Loss:
$-1.16B
P/E Ratio:
-4.5953
EPS:
-26.61
Net Cash Flow:
$282.00M
1W Performance:
+4.13%
1M Performance:
-8.61%
6M Performance:
+9.54%
1Y Performance:
-42.04%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
858-202-4500
Address
5200 Illumina Way, San Diego, CA
Illumina Inc Stock (ILMN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-14-23 | Initiated | Stephens | Overweight |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Sep-28-23 | Initiated | Bernstein | Underperform |
Jul-05-23 | Resumed | JP Morgan | Neutral |
Jan-25-23 | Downgrade | Argus | Buy → Hold |
Jan-05-23 | Initiated | Scotiabank | Sector Perform |
Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-18-22 | Upgrade | Stifel | Hold → Buy |
Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-03-21 | Initiated | Barclays | Underweight |
Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Sep-22-20 | Downgrade | Stifel | Buy → Hold |
Sep-22-20 | Downgrade | UBS | Buy → Neutral |
Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jan-08-20 | Initiated | Wells Fargo | Underweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-15-19 | Initiated | Stifel | Buy |
Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Zacks Investment Research
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Zacks Investment Research
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Zacks Investment Research
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'
Benzinga
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Illumina Inc Stock (ILMN) Financials Data
Illumina Inc (ILMN) Revenue 2024
ILMN reported a revenue (TTM) of $4.50 billion for the quarter ending December 31, 2023, a -1.72% decline year-over-year.
Illumina Inc (ILMN) Net Income 2024
ILMN net income (TTM) was -$1.16 billion for the quarter ending December 31, 2023, a +73.66% increase year-over-year.
Illumina Inc (ILMN) Cash Flow 2024
ILMN recorded a free cash flow (TTM) of $282.00 million for the quarter ending December 31, 2023, a +481.08% increase year-over-year.
Illumina Inc (ILMN) Earnings per Share 2024
ILMN earnings per share (TTM) was -$7.34 for the quarter ending December 31, 2023, a +73.79% growth year-over-year.
About Illumina Inc
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):